Newbridge Financial Services Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.29K | Sell |
106
-100
| -49% | -$7.82K | ﹤0.01% | 932 |
|
|
2025
Q1 | $14.9K | Hold |
206
| – | – | ﹤0.01% | 606 |
|
|
2024
Q4 | $15.3K | Buy |
+206
| New | +$15.3K | ﹤0.01% | 661 |
|
|
2024
Q3 | – | Sell |
-135
| Closed | -$12.5K | – | 786 |
|
|
2024
Q2 | $12.5K | Sell |
135
-274
| -67% | -$25.3K | ﹤0.01% | 666 |
|
|
2024
Q1 | $39.1K | Sell |
409
-1,968
| -83% | -$188K | 0.02% | 444 |
|
|
2023
Q4 | $181K | Sell |
2,377
-136
| -5% | -$10.4K | 0.09% | 201 |
|
|
2023
Q3 | $174K | Buy |
2,513
+35
| +1% | +$2.43K | 0.09% | 203 |
|
|
2023
Q2 | $234K | Buy |
2,478
+13
| +0.5% | +$1.23K | 0.11% | 183 |
|
|
2023
Q1 | $204K | Sell |
2,465
-14
| -0.6% | -$1.16K | 0.11% | 184 |
|
|
2022
Q4 | $185K | Buy |
2,479
+27
| +1% | +$2.01K | 0.11% | 189 |
|
|
2022
Q3 | $203K | Sell |
2,452
-16
| -0.6% | -$1.33K | 0.12% | 185 |
|
|
2022
Q2 | $235K | Buy |
2,468
+132
| +6% | +$12.6K | 0.15% | 145 |
|
|
2022
Q1 | $275K | Buy |
2,336
+64
| +3% | +$7.53K | 0.14% | 146 |
|
|
2021
Q4 | $294K | Buy |
2,272
+2,070
| +1,025% | +$268K | 0.14% | 152 |
|
|
2021
Q3 | $23K | Sell |
202
-60
| -23% | -$6.83K | 0.01% | 620 |
|
|
2021
Q2 | $27K | Sell |
262
-50
| -16% | -$5.15K | 0.02% | 682 |
|
|
2021
Q1 | $26K | Sell |
312
-120
| -28% | -$10K | 0.02% | 613 |
|
|
2020
Q4 | $39K | Sell |
432
-300
| -41% | -$27.1K | 0.03% | 386 |
|
|
2020
Q3 | $58K | Buy |
+732
| New | +$58K | 0.06% | 292 |
|